Abeona Therapeutics (PCJ) Stock Statistics & Valuation Metrics
Total Valuation
Abeona Therapeutics has a market cap or net worth of CHF 197.89M. The enterprise value is CHF 225.61M.
- Market Cap
- CHF 197.89M
- Enterprise Value
- CHF 225.61M
Share Statistics
Abeona Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- ―
- Owned by Insiders
- 6.19%
- Owned by Institutions
- 21.68%
Financial Efficiency
Abeona Therapeutics’s return on equity (ROE) is 0.45 and return on invested capital (ROIC) is -43.98%.
- Return on Equity (ROE)
- 0.45
- Return on Assets (ROA)
- 0.32
- Return on Invested Capital (ROIC)
- -43.98%
- Return on Capital Employed (ROCE)
- -0.47
- Revenue Per Employee
- 25.75K
- Profits Per Employee
- 314.97K
- Employee Count
- 226
- Asset Turnover
- 0.03
- Inventory Turnover
- 0.28
Valuation Ratios
The current PE Ratio of Abeona Therapeutics is -3.72. Abeona Therapeutics’s PEG ratio is 0.02.
- PE Ratio
- -3.72
- PS Ratio
- 9.46
- PB Ratio
- 1.88
- Price to FCF
- -2.96
- Price to Operating Cash Flow
- -3.15
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Abeona Therapeutics had revenue of 5.82M and earned 71.18M in profits. Earnings per share was 1.34.
- Revenue
- 5.82M
- Gross Profit
- 4.29M
- Operating Income
- -89.45M
- Pretax Income
- 71.28M
- Net Income
- 71.18M
- EBITDA
- 78.59M
- Earnings Per Share (EPS)
- 1.34
Cash Flow
In the last 12 months, operating cash flow was -76.44M and capital expenditures -5.09M, giving a free cash flow of -81.53M billion.
- Operating Cash Flow
- -76.44M
- Free Cash Flow
- -81.53M
- Free Cash Flow per Share
- -1.43
Dividends & Yields
Abeona Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -36.46%
- Earnings Yield
- -28.19%
Important Dates
Abeona Therapeutics upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Abeona Therapeutics as a current ratio of 6.93, with Debt / Equity ratio of 15.68%
- Current Ratio
- 6.93
- Quick Ratio
- 6.74
- Debt to Market Cap
- 0.07
- Net Debt to EBITDA
- -0.68
- Interest Coverage Ratio
- -23.92
Taxes
In the past 12 months, Abeona Therapeutics has paid 100.00K in taxes.
- Income Tax
- 100.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Abeona Therapeutics EV to EBITDA ratio is -2.63, with an EV/FCF ratio of -2.30.
- EV to Sales
- 7.34
- EV to EBITDA
- -2.63
- EV to Free Cash Flow
- -2.30
- EV to Operating Cash Flow
- -2.45
Balance Sheet
Abeona Therapeutics has CHF 146.83M in cash and marketable securities with CHF 19.87M in debt, giving a net cash position of CHF 126.95M billion.
- Cash & Marketable Securities
- CHF 146.83M
- Total Debt
- CHF 19.87M
- Net Cash
- CHF 126.95M
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- CHF 2.24
Margins
Gross margin is 56.63%, with operating margin of -327.64%, and net profit margin of -246.42%.
- Gross Margin
- 56.63%
- Operating Margin
- -327.64%
- Pretax Margin
- -306.81%
- Net Profit Margin
- -246.42%
- EBITDA Margin
- -279.40%
- EBIT Margin
- -293.83%
Analyst Forecast
The average price target for Abeona Therapeutics is CHF 18.03, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- CHF 18.03
- Price Target Upside
- ―
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 5
- AI Score
- ―
